Noxopharm Ltd (NOX) - Total Assets
Based on the latest financial reports, Noxopharm Ltd (NOX) holds total assets worth AU$4.58 Million AUD (≈ $3.24 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NOX net assets for net asset value and shareholders' equity analysis.
Noxopharm Ltd - Total Assets Trend (2016–2025)
This chart illustrates how Noxopharm Ltd's total assets have evolved over time, based on quarterly financial data.
Noxopharm Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Noxopharm Ltd's total assets of AU$4.58 Million consist of 99.9% current assets and 0.1% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 33.9% |
| Accounts Receivable | AU$2.95 Million | 64.3% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Noxopharm Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NOX stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Noxopharm Ltd's current assets represent 99.9% of total assets in 2025, an increase from 99.7% in 2016.
- Cash Position: Cash and equivalents constituted 33.9% of total assets in 2025, down from 99.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 64.3% of total assets.
Noxopharm Ltd Competitors by Total Assets
Key competitors of Noxopharm Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €1.30 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.69 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
Noxopharm Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.18 | 3.83 | 1.84 |
| Quick Ratio | 1.18 | 5.72 | 1.77 |
| Cash Ratio | 0.40 | 1.86 | 1.06 |
| Working Capital | AU$707.27K | AU$3.52 Million | AU$5.64 Million |
Noxopharm Ltd - Advanced Valuation Insights
This section examines the relationship between Noxopharm Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 31.77 |
| Latest Market Cap to Assets Ratio | 3.16 |
| Asset Growth Rate (YoY) | -32.5% |
| Total Assets | AU$4.58 Million |
| Market Capitalization | $14.47 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Noxopharm Ltd's assets at a significant premium (3.16x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Noxopharm Ltd's assets decreased by 32.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Noxopharm Ltd (2016–2025)
The table below shows the annual total assets of Noxopharm Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$4.58 Million ≈ $3.24 Million |
-32.47% |
| 2024-06-30 | AU$6.78 Million ≈ $4.80 Million |
-33.02% |
| 2023-06-30 | AU$10.13 Million ≈ $7.17 Million |
-61.91% |
| 2022-06-30 | AU$26.59 Million ≈ $18.82 Million |
-44.43% |
| 2021-06-30 | AU$47.85 Million ≈ $33.86 Million |
+138.47% |
| 2020-06-30 | AU$20.07 Million ≈ $14.20 Million |
+366.63% |
| 2019-06-30 | AU$4.30 Million ≈ $3.04 Million |
-70.44% |
| 2018-06-30 | AU$14.55 Million ≈ $10.29 Million |
+414.37% |
| 2017-06-30 | AU$2.83 Million ≈ $2.00 Million |
-54.43% |
| 2016-06-30 | AU$6.21 Million ≈ $4.39 Million |
-- |
About Noxopharm Ltd
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug… Read more